Skip to main content
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. — Investor Relations & Filings

Ticker · DSGN ISIN · US25056L1035 US Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2022-05-05 Regulatory Filings
Country US United States of America
Listing US DSGN

About Design Therapeutics, Inc.

https://www.designtx.com/

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of small molecule therapies for genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform is used to design therapeutic candidates that target the underlying cause of genetic disorders. These molecules are engineered to modulate gene expression—either increasing or decreasing it as needed—without requiring gene editing. The company's initial focus is on monogenic diseases driven by nucleotide repeat expansions, with programs targeting conditions such as Friedreich ataxia, myotonic dystrophy, Fuchs endothelial corneal dystrophy, and Huntington’s disease. The company aims to develop functional cures for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a securities registration filing, specifically a request for the registration statement to become effective sooner. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising but is not itself a capital/financing update report or a registration statement. Given its nature as a formal regulatory correspondence requesting action on a filing, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories. The document length is short (2052 characters), and it is not a report publication announcement or certification. Therefore, the classification is RNS with high confidence.
2022-05-05 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a securities registration process, specifically concerning the timing of the effectiveness of a registration statement. The document is short (1381 characters) and does not contain financial data, audit information, or detailed report content. It is not a report itself but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-05-02 English
Regulatory Filings 2022
Regulatory Filings
2022-04-29 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the offering, issuance, and sale of securities including common stock, preferred stock, debt securities, and warrants. The document includes a base prospectus and sales agreement prospectus, describing the terms and conditions of securities offerings. This type of filing is related to capital raising activities and financing, not an annual report, earnings release, or other types of reports. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual registration statement document.
2022-04-27 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement related to the Annual Meeting of Stockholders. It includes information about the meeting date, location, proposals to be voted on (such as election of directors and ratification of auditors), and instructions for accessing proxy materials. The content is typical of proxy solicitation materials sent to shareholders to inform them and request votes for the meeting. The document is not the actual annual report, earnings release, or other financial report, but rather proxy solicitation information. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length is 3675 characters, which is consistent with a proxy statement or related materials rather than a full report.
2022-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.